智通财经网·2025-11-13 11:24Core Viewpoint - Pfizer is seeking to sell its remaining stake in COVID-19 vaccine partner BioNTech, marking the end of a highly profitable collaboration during the pandemic [1] Group 1: Pfizer's Stake Sale - Pfizer plans to sell approximately 4.55 million American Depositary Receipts (ADRs) at a price range of $108 to $111.70 per share, potentially generating about $508 million if priced at the upper limit [1] - The collaboration between Pfizer and BioNTech began in 2020, resulting in billions of dollars in revenue from the COVID-19 vaccine and supply agreements with the U.S. and EU governments [1] Group 2: Ongoing Collaboration and Future Plans - Pfizer and BioNTech continue to collaborate on developing COVID-19 vaccine formulations based on BioNTech's proprietary mRNA technology, sharing revenues from this ongoing partnership [1] - Pfizer recently acquired obesity startup Metsera Inc. for $10 billion, aiming to replace declining COVID-19 business revenues with a new weight-loss drug [1] Group 3: BioNTech's Shift in Focus - With the pandemic subsiding, BioNTech is returning to its original focus on cancer treatment research, utilizing accumulated funds to support this research [1] - BioNTech has also entered into a collaboration agreement with Bristol Myers Squibb valued at up to $11.1 billion [1]